Information Provided By: 
Fly News Breaks for May 28, 2015
ACT
May 28, 2015 | 09:17 EDT
BMO Capital says that FDA approval of Actavis' new drug for irritable bowel syndrome associated with diarrhea, Viberzi, is "great news" for the company. The firm thinks that Viberzi will be very complimentary to Linzess and future GI products, and it expects the launch to be successful. The firm keeps an Outperform rating on the shares.
News For ACT From the Last 2 Days
There are no results for your query ACT
